Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: RPL22L1

Gene summary for RPL22L1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

RPL22L1

Gene ID

200916

Gene nameribosomal protein L22 like 1
Gene AliasRPL22L1
Cytomap3q26.2
Gene Typeprotein-coding
GO ID

GO:0002181

UniProtAcc

Q6P5R6


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
200916RPL22L1PTC07HumanThyroidPTC4.34e-357.65e-010.2044
200916RPL22L1ATC08HumanThyroidATC6.73e-03-9.08e-020.0541
200916RPL22L1ATC09HumanThyroidATC1.85e-07-3.88e-020.2871
200916RPL22L1ATC11HumanThyroidATC6.50e-091.89e+000.3386
200916RPL22L1ATC12HumanThyroidATC1.07e-08-1.75e-030.34
200916RPL22L1ATC13HumanThyroidATC1.49e-142.12e-010.34
200916RPL22L1ATC2HumanThyroidATC1.14e-142.61e+000.34
200916RPL22L1ATC3HumanThyroidATC1.10e-101.74e+000.338
200916RPL22L1ATC4HumanThyroidATC1.64e-059.28e-020.34
200916RPL22L1ATC5HumanThyroidATC5.12e-162.67e-010.34
Page: 1 2 3 4 5 6 7 8 9 10 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
CervixThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.CC: Cervix cancer
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:000218110CervixCCcytoplasmic translation96/2311148/187234.87e-512.91e-4796
GO:000218115CervixHSIL_HPVcytoplasmic translation86/737148/187233.97e-821.91e-7886
GO:000218125CervixN_HPVcytoplasmic translation42/534148/187232.61e-301.19e-2642
GO:0002181ColorectumADcytoplasmic translation109/3918148/187233.40e-432.13e-39109
GO:00021811ColorectumSERcytoplasmic translation102/2897148/187231.38e-488.49e-45102
GO:00021812ColorectumMSScytoplasmic translation108/3467148/187231.78e-471.11e-43108
GO:00021813ColorectumMSI-Hcytoplasmic translation100/1319148/187231.50e-798.31e-76100
GO:000218116EndometriumAEHcytoplasmic translation104/2100148/187231.01e-646.07e-61104
GO:000218117EndometriumEECcytoplasmic translation104/2168148/187232.53e-631.52e-59104
GO:0002181111EsophagusESCCcytoplasmic translation135/8552148/187234.17e-322.65e-29135
GO:000218112LiverCirrhoticcytoplasmic translation120/4634148/187232.95e-471.85e-43120
GO:000218122LiverHCCcytoplasmic translation132/7958148/187239.09e-335.76e-30132
GO:000218120Oral cavityOSCCcytoplasmic translation133/7305148/187231.94e-382.46e-35133
GO:0002181110Oral cavityLPcytoplasmic translation124/4623148/187235.09e-523.19e-48124
GO:000218118ProstateBPHcytoplasmic translation115/3107148/187231.08e-606.68e-57115
GO:000218119ProstateTumorcytoplasmic translation115/3246148/187231.36e-588.43e-55115
GO:000218129SkincSCCcytoplasmic translation127/4864148/187234.83e-537.57e-50127
GO:0002181113ThyroidPTCcytoplasmic translation121/5968148/187234.32e-364.54e-33121
GO:000218135ThyroidATCcytoplasmic translation121/6293148/187231.41e-331.49e-30121
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa0517120CervixCCCoronavirus disease - COVID-19111/1267232/84651.82e-335.90e-313.49e-31111
hsa0301020CervixCCRibosome85/1267167/84653.17e-285.14e-263.04e-2685
hsa05171110CervixCCCoronavirus disease - COVID-19111/1267232/84651.82e-335.90e-313.49e-31111
hsa03010110CervixCCRibosome85/1267167/84653.17e-285.14e-263.04e-2685
hsa0301025CervixHSIL_HPVRibosome80/459167/84659.61e-582.82e-552.28e-5580
hsa0517125CervixHSIL_HPVCoronavirus disease - COVID-1991/459232/84652.14e-563.13e-542.53e-5491
hsa0301035CervixHSIL_HPVRibosome80/459167/84659.61e-582.82e-552.28e-5580
hsa0517135CervixHSIL_HPVCoronavirus disease - COVID-1991/459232/84652.14e-563.13e-542.53e-5491
hsa0517145CervixN_HPVCoronavirus disease - COVID-1947/349232/84651.79e-204.86e-183.80e-1847
hsa0301045CervixN_HPVRibosome39/349167/84652.05e-192.79e-172.18e-1739
hsa0517155CervixN_HPVCoronavirus disease - COVID-1947/349232/84651.79e-204.86e-183.80e-1847
hsa0301055CervixN_HPVRibosome39/349167/84652.05e-192.79e-172.18e-1739
hsa03010ColorectumADRibosome96/2092167/84658.28e-205.54e-183.54e-1896
hsa05171ColorectumADCoronavirus disease - COVID-19113/2092232/84659.90e-162.55e-141.63e-14113
hsa030101ColorectumADRibosome96/2092167/84658.28e-205.54e-183.54e-1896
hsa051711ColorectumADCoronavirus disease - COVID-19113/2092232/84659.90e-162.55e-141.63e-14113
hsa030104ColorectumMSSRibosome96/1875167/84651.82e-232.03e-211.24e-2196
hsa051714ColorectumMSSCoronavirus disease - COVID-19108/1875232/84656.50e-171.67e-151.03e-15108
hsa030105ColorectumMSSRibosome96/1875167/84651.82e-232.03e-211.24e-2196
hsa051715ColorectumMSSCoronavirus disease - COVID-19108/1875232/84656.50e-171.67e-151.03e-15108
Page: 1 2 3 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
RPL22L1SNVMissense_Mutationnovelc.361N>Cp.Glu121Glnp.E121QQ6P5R6protein_codingdeleterious(0)benign(0.305)TCGA-BH-A0B6-01Breastbreast invasive carcinomaFemale<65I/IIUnknownUnknownSD
RPL22L1SNVMissense_Mutationnovelc.317N>Gp.Leu106Argp.L106RQ6P5R6protein_codingdeleterious(0)probably_damaging(0.999)TCGA-A6-2672-01Colorectumcolon adenocarcinomaFemale>=65III/IVUnknownUnknownSD
RPL22L1SNVMissense_Mutationc.151N>Ap.Leu51Ilep.L51IQ6P5R6protein_codingdeleterious(0.02)probably_damaging(0.984)TCGA-AP-A059-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
RPL22L1SNVMissense_Mutationc.151N>Ap.Leu51Ilep.L51IQ6P5R6protein_codingdeleterious(0.02)probably_damaging(0.984)TCGA-B5-A1MR-01Endometriumuterine corpus endometrioid carcinomaFemale>=65III/IVUnknownUnknownSD
RPL22L1SNVMissense_Mutationrs761781205c.313G>Ap.Glu105Lysp.E105KQ6P5R6protein_codingtolerated(0.13)possibly_damaging(0.537)TCGA-D1-A103-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
RPL22L1SNVMissense_Mutationnovelc.55N>Ap.Asp19Asnp.D19NQ6P5R6protein_codingtolerated(0.12)possibly_damaging(0.651)TCGA-DF-A2KU-01Endometriumuterine corpus endometrioid carcinomaFemaleUnknownI/IIUnknownUnknownSD
RPL22L1SNVMissense_Mutationc.319C>Tp.Arg107Cysp.R107CQ6P5R6protein_codingtolerated(0.12)benign(0.081)TCGA-E6-A1LX-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
RPL22L1SNVMissense_Mutationrs200190593c.115N>Tp.Arg39Trpp.R39WQ6P5R6protein_codingtolerated(0.18)benign(0.022)TCGA-EO-A22U-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
RPL22L1SNVMissense_Mutationc.319N>Tp.Arg107Cysp.R107CQ6P5R6protein_codingtolerated(0.12)benign(0.081)TCGA-EO-A3AV-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinCR
RPL22L1SNVMissense_Mutationnovelc.23N>Tp.Lys8Metp.K8MQ6P5R6protein_codingdeleterious(0)probably_damaging(0.951)TCGA-56-7823-01Lunglung squamous cell carcinomaFemale<65I/IIChemotherapycisplatinCR
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1